#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...
Learn more about the study www.gbg.de/en/trials/ge...
GeparPiPPa
Phase II trial comparing neoadjuvant endocrine therapy in combination with the PI3K-Inhibitor Inavolisib
www.gbg.de
October 24, 2025 at 3:38 PM
#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...
Learn more about the study www.gbg.de/en/trials/ge...